Company intelligence / Profile preview

TH Bamboo

Chapel Hill, North Carolina, United Statesbambootherapeutics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Bamboo Therapeutics developed AAV-based gene therapies for rare neuromuscular and CNS diseases. Lead programs included preclinical work in Duchenne muscular dystrophy, Friedreich ataxia, and Canavan disease. The company was acquired by Pfizer before initiating clinical trials; subsequent development continued within Pfizer's pipeline.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: AAV-based gene therapySmall molecule
Industry: Biotech

Partnerships

CureDuchenne Ventures

Beyond the preview

Go deeper on TH Bamboo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TH Bamboo.